<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01973062</url>
  </required_header>
  <id_info>
    <org_study_id>CASE4413</org_study_id>
    <secondary_id>NCI-2013-01993</secondary_id>
    <nct_id>NCT01973062</nct_id>
  </id_info>
  <brief_title>Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma</brief_title>
  <official_title>Phase II Study of Radioimmunotherapy With Zevalin (Ibritumomab Tiuxetan) Therapy for Patients With Refractory or Relapsed Primary Central Nervous System Lymphoma (PCNSL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well yttrium Y 90 ibritumomab tiuxetan and rituximab work in
      treating patients with recurrent or refractory primary central nervous system non-Hodgkin
      lymphoma. Radiolabeled monoclonal antibodies, such as yttrium 90 ibritumomab tiuxetan, can
      find cancer cells and carry cancer-killing substances to them without harming normal cells.
      Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some
      block the ability of cancer to grow and spread. Others find cancer cells and help kill them
      or carry cancer-killing substances to them. Giving yttrium Y 90 ibritumomab tiuxetan with
      rituximab may kill more cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the radiographic response proportion in patients with refractory or recurrent
      primary central nervous system lymphoma (PCNSL) to ibritumomab tiuxetan (yttrium Y 90
      ibritumomab tiuxetan) when given as an intravenous infusion.

      SECONDARY OBJECTIVES:

      I. Determine the progression free survival of patients treated with ibritumomab tiuxetan when
      given as an intravenous infusion.

      II. Determine the overall survival of patients treated with ibritumomab tiuxetan when given
      as an intravenous infusion.

      III. Establish the toxicity profile of ibritumomab tiuxetan in this patient population.

      IV. Use positron emission tomography (PET)/magnetic resonance imaging (MRI) to map the
      distribution of Y-90 ibritumomab tiuxetan, and calculate the Gy delivered based on the
      activity found within tumor.

      OUTLINE:

      Patients receive rituximab intravenously (IV) on day 1. Within 7 to 9 days, patients receive
      rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression
      or unacceptable toxicity. Distribution and dose absorbed dose will be assessed on day 11.
      Quality of life will be assessed at screening, at day 1, 36, 92, and at each follow-up visit.

      After completion of study treatment, patients are followed every 3-6 months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding Unavailable
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic Response Assessed by MRI or FDG-PET/MRI</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of patients with at least a 50% reduction in tumor size on a MRI scan with stable or decreasing dose of corticosteroids</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The number of patients without an unequivocal increase in tumor size or the appearance of new lesions by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The number of patients alive up to two years after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish the Toxicity Profile of Ibritumomab Tiuxetan in This Patient Population.</measure>
    <time_frame>Up to 30 days following the last dose of study treatment</time_frame>
    <description>Number of patients with toxicities related to the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosimetry Calculations of Yttrium Y 90 Ibritumomab Tiuxetan Assessed by PET/MRI</measure>
    <time_frame>At day 11</time_frame>
    <description>Number of Gy delivered to each tumor as calculated using the MIRD dosimetry formula on PET data</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Primary Central Nervous System Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>rituximab and yttrium Y 90 ibritumomab tiuxetan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>rituximab and yttrium Y 90 ibritumomab tiuxetan</arm_group_label>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 monoclonal antibody</other_name>
    <other_name>Mabthera</other_name>
    <other_name>MOAB IDEC-C2B8</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 ibritumomab tiuxetan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>rituximab and yttrium Y 90 ibritumomab tiuxetan</arm_group_label>
    <other_name>90Y ibritumomab tiuxetan</other_name>
    <other_name>IDEC Y2B8</other_name>
    <other_name>Y90 Zevalin</other_name>
    <other_name>Y90-labeled ibritumomab tiuxetan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histological diagnosis of recurrent or refractory primary central
             nervous system (CNS) lymphoma with at least 1 measurable gadolinium enhancing lesion
             on brain MRI scans

          -  Karnofsky performance status (KPS) &gt;= 60

          -  Patients could not have had more than 3 prior therapy regimens for the treatment of
             PCNSL

          -  Absolute neutrophil count (ANC) &gt;= 1.5 x 10^9/L

          -  Platelets &gt;= 100 x 10^9/L

          -  Hemoglobin (Hgb) &gt; 10 g/dL

          -  Serum total bilirubin =&lt; 1.5 x upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT) =&lt; 3.0 x ULN

          -  Aspartate aminotransferase (AST) =&lt; 3.0 x ULN

          -  Serum creatinine =&lt; 1.5 x ULN

          -  Minimum interval since completion of radiation treatment is 12 weeks

          -  Minimum interval since last drug therapy:

               -  3 weeks since the completion of non-cytotoxic agents

               -  4 weeks since the completion of a non-nitrosourea-containing regimen

               -  6 weeks since the completion of a nitrosourea-containing regimen

          -  Patients must have signed an approved informed consent and authorization permitting
             release of personal health information

          -  Patients are not on corticosteroids or on stable doses (less than 6 mg daily of
             dexamethasone) for more than 1 week before baseline imaging

          -  Patients with the potential for pregnancy or impregnating their partner must agree to
             follow acceptable birth control methods to avoid conception

          -  Patients must have no concurrent malignancy except curatively treated basal or
             squamous cell carcinoma of the skin or carcinoma in situ of the cervix and breast,
             adequately treated stage I or II cancer from which the patient is in complete
             remission; patients with other prior malignancies must be disease-free for &gt;= three
             years

        Exclusion Criteria:

          -  Pregnant or breast-feeding women

          -  Patients unwilling or unable to comply with the protocol

          -  Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g.
             active infection, uncontrolled diabetes, symptomatic congestive heart failure,
             unstable angina, cardiac arrhythmia, or psychiatric illness, etc.) that could cause
             unacceptable safety risks or compromise compliance with the protocol

          -  Known diagnosis of human immunodeficiency virus (HIV) infection; prior
             radioimmunotherapy, prior myeloablative therapy with autologous bone marrow
             transplantation or peripheral stem cell rescue, and prior external beam radiation
             therapy to more than 25% of active bone marrow

          -  Patients who have received filgrastim (G-CSF) or sargramostim (GM-CSF) within 2 weeks
             before treatment or major surgery within the prior 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manmeet Ahluwalia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 25, 2013</study_first_submitted>
  <study_first_submitted_qc>October 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2013</study_first_posted>
  <results_first_submitted>June 25, 2018</results_first_submitted>
  <results_first_submitted_qc>June 25, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 20, 2018</results_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</title>
          <description>Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.
rituximab: Given IV
yttrium Y 90 ibritumomab tiuxetan: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</title>
          <description>Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.
rituximab: Given IV
yttrium Y 90 ibritumomab tiuxetan: Given IV</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Radiographic Response Assessed by MRI or FDG-PET/MRI</title>
        <description>Number of patients with at least a 50% reduction in tumor size on a MRI scan with stable or decreasing dose of corticosteroids</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Only one patient registered. No patient data analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</title>
            <description>Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.
rituximab: Given IV
yttrium Y 90 ibritumomab tiuxetan: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Radiographic Response Assessed by MRI or FDG-PET/MRI</title>
          <description>Number of patients with at least a 50% reduction in tumor size on a MRI scan with stable or decreasing dose of corticosteroids</description>
          <population>Only one patient registered. No patient data analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>The number of patients without an unequivocal increase in tumor size or the appearance of new lesions by MRI</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Only one patient registered. No patient data analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</title>
            <description>Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.
rituximab: Given IV
yttrium Y 90 ibritumomab tiuxetan: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>The number of patients without an unequivocal increase in tumor size or the appearance of new lesions by MRI</description>
          <population>Only one patient registered. No patient data analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The number of patients alive up to two years after treatment</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Only one patient registered. No patient data analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</title>
            <description>Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.
rituximab: Given IV
yttrium Y 90 ibritumomab tiuxetan: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The number of patients alive up to two years after treatment</description>
          <population>Only one patient registered. No patient data analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Establish the Toxicity Profile of Ibritumomab Tiuxetan in This Patient Population.</title>
        <description>Number of patients with toxicities related to the study drug</description>
        <time_frame>Up to 30 days following the last dose of study treatment</time_frame>
        <population>Only one patient registered. No patient data analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</title>
            <description>Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.
rituximab: Given IV
yttrium Y 90 ibritumomab tiuxetan: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Establish the Toxicity Profile of Ibritumomab Tiuxetan in This Patient Population.</title>
          <description>Number of patients with toxicities related to the study drug</description>
          <population>Only one patient registered. No patient data analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dosimetry Calculations of Yttrium Y 90 Ibritumomab Tiuxetan Assessed by PET/MRI</title>
        <description>Number of Gy delivered to each tumor as calculated using the MIRD dosimetry formula on PET data</description>
        <time_frame>At day 11</time_frame>
        <population>Only one patient registered. No patient data analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</title>
            <description>Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.
rituximab: Given IV
yttrium Y 90 ibritumomab tiuxetan: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Dosimetry Calculations of Yttrium Y 90 Ibritumomab Tiuxetan Assessed by PET/MRI</title>
          <description>Number of Gy delivered to each tumor as calculated using the MIRD dosimetry formula on PET data</description>
          <population>Only one patient registered. No patient data analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</title>
          <description>Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.
rituximab: Given IV
yttrium Y 90 ibritumomab tiuxetan: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manmeet Ahluwalia, MD</name_or_title>
      <organization>Case Comprehensive Cancer Center</organization>
      <phone>216-444-6145</phone>
      <email>ahluwam@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

